Rivastigmine
Treatment for Alzheimers Disease
Typical Dosage: 1.5-6 mg orally twice daily, or 4.6-13.3 mg/24h transdermal patch
Effectiveness
43%
Safety Score
58%
Clinical Trials
55
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
1.5-6 mg orally twice daily, or 4.6-13.3 mg/24h transdermal patch
Time to Effect
4-6 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$400
Side Effect Mgmt:$50
Total Annual:$600
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.04
Outcome-Based Costs
Cost per Responder
$2,400
Rivastigmine Outcomes
for Alzheimers Disease
Efficacy Outcomes
Overall Effectiveness
+43%
Response Rate
+25%
Common Side Effects
Nausea
+10%
Vomiting
+7%
Skin irritation (patch)
+12%
Diarrhea
+4%
Dizziness
+6%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
19 completed trials for Rivastigmine in Alzheimers Disease
Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
NCT01585272COMPLETEDPHASE4
121 participants
INTERVENTIONAL
Taichung, Taiwan +3 more
Started: Aug 1, 2012
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
NCT02989402COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Bangalore, India +8 more
Started: Dec 31, 2018
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
NCT01399125COMPLETEDPHASE3
501 participants
INTERVENTIONAL
Fuzhou, China +15 more
Started: Jul 1, 2011
Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients
NCT01312363COMPLETED
300 participants
OBSERVATIONAL
Busan, South Korea +18 more
Started: Jun 1, 2009
Rivastigmine in Mild Alzheimer's Disease, FMRI Study
NCT00627848COMPLETEDNA
20 participants
INTERVENTIONAL
Kuopio, Finland
Started: Mar 1, 2007
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
NCT01047579COMPLETEDPHASE4
51 participants
INTERVENTIONAL
Ashkelon, Israel +4 more
Started: Apr 1, 2010
Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
NCT01380288COMPLETEDNA
300 participants
INTERVENTIONAL
Bucheon-si, South Korea +15 more
Started: Jun 1, 2011
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
NCT00104442COMPLETEDPHASE4
80 participants
INTERVENTIONAL
East Hanover, United States
Started: Oct 1, 2003
Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD
NCT02444637COMPLETEDPHASE4
100 participants
INTERVENTIONAL
Singapore, Singapore
Started: Apr 1, 2015
16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
NCT01948791COMPLETEDPHASE4
222 participants
INTERVENTIONAL
Beijing, China
Started: Aug 1, 2014
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
NCT00622713COMPLETEDPHASE4
228 participants
INTERVENTIONAL
Rueil-Malmaison, France
Started: Jan 1, 2008
Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
NCT01183806COMPLETEDPHASE3
40 participants
INTERVENTIONAL
Salvador, Brazil +1 more
Started: Jul 1, 2010
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
NCT00234637COMPLETEDPHASE4
204 participants
INTERVENTIONAL
Limoges, France
Started: Nov 1, 2003
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
NCT02703636COMPLETEDPHASE4
118 participants
INTERVENTIONAL
Fukuoka, Japan +18 more
Started: May 9, 2016
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
NCT00305903COMPLETEDPHASE4
150 participants
INTERVENTIONAL
Paterson, United States
Started: Mar 1, 2006
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
NCT01529619COMPLETEDPHASE4
52 participants
INTERVENTIONAL
Nagoya, Japan +10 more
Started: Mar 1, 2012
Exelon Patch and Combination With Memantine Comparative Trial
NCT01025466COMPLETEDPHASE4
206 participants
INTERVENTIONAL
Bucheon-si, South Korea +25 more
Started: Dec 1, 2008
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
NCT00731224COMPLETEDPHASE4
380 participants
INTERVENTIONAL
East Gosford, Australia +39 more
Started: Jul 1, 2008
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
NCT00000174COMPLETEDPHASE3
INTERVENTIONAL
Peoria, United States +14 more
Showing 20 of 55 total trials